4.8 Article

Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference

期刊

NATURE COMMUNICATIONS
卷 9, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-018-05892-0

关键词

-

资金

  1. EPSRC
  2. Biomarkers Across Neurodegenerative Diseases programme
  3. Michael J. Fox Foundation for Parkinson's Research
  4. Alzheimer's Association
  5. Alzheimer's Research UK
  6. Weston Brain Institute
  7. EPSRC Centre For Doctoral Training in Medical Imaging [EP/L016478/1]
  8. UCL Leonard Wolfson Experimental Neurology Centre [PR/ylr/18575]
  9. Alzheimer's Society PhD Studentship
  10. Wellcome Trust [103838]
  11. Associazione Italiana Ricerca Alzheimer ONLUS (AIRAlzh Onlus)-COOP Italia
  12. Alzheimer's Society
  13. NIHR UCLH Biomedical Research Centre
  14. NIHR Queen Square Dementia BRU
  15. ARUK [ART-SRF2010-3, ARUK-Network 2012-6-ICE, ARUK-PG2017-1946]
  16. ESRC/NIHR [ES/L001810/1]
  17. EPSRC [EP/M006093/1, EP/J020990/1, EP/J020990/01, EP/M020533/1]
  18. NIHR UCL/H Biomedical Research Centre
  19. Wolfson Foundation
  20. MRC [MR/L023784/1]
  21. Brain Research Trust [UCC14191]
  22. European Union's Horizon 2020 research and innovation programme [666992]
  23. MRC Clinician Scientist Fellowship [MR/M008525/1]
  24. NIHR Rare Disease Translational Research Collaboration
  25. Brain Research Trust
  26. NIHR Queen Square Dementia Biomedical Research Unit
  27. European Union [666992]
  28. MRC UK GENFI [MR/M023664/1]
  29. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  30. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  31. National Institute on Aging
  32. National Institute of Biomedical Imaging and Bioengineering
  33. AbbVie
  34. Alzheimer's Drug Discovery Foundation
  35. Araclon Biotech
  36. BioClinica, Inc.
  37. Biogen
  38. Bristol-Myers Squibb Company
  39. CereSpir, Inc.
  40. Cogstate
  41. Eisai Inc.
  42. Elan Pharmaceuticals, Inc.
  43. Eli Lilly and Company
  44. EuroImmun
  45. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  46. Fujirebio
  47. GE Healthcare
  48. IXICO Ltd.
  49. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  50. Johnson & Johnson Pharmaceutical Research & Development LLC.
  51. Lumosity
  52. Lundbeck
  53. Merck Co., Inc.
  54. Meso Scale Diagnostics, LLC.
  55. NeuroRx Research
  56. Neurotrack Technologies
  57. Novartis Pharmaceuticals Corporation
  58. Pfizer Inc.
  59. Piramal Imaging
  60. Servier
  61. Takeda Pharmaceutical Company
  62. Transition Therapeutics
  63. Canadian Institutes of Health Research
  64. EPSRC [EP/J020990/1, EP/M020533/1, EP/M006093/1] Funding Source: UKRI
  65. ESRC [ES/L001810/1] Funding Source: UKRI
  66. MRC [MC_U105597119, G0601846, MR/M008525/1, MC_UU_00005/12, MR/J009482/1, MR/M024873/1, MR/M023664/1, G116/143, MR/M009041/1, G0801306, G0401247, UKDRI-1001, MR/M009106/1, MC_UU_00024/1] Funding Source: UKRI
  67. Engineering and Physical Sciences Research Council [EP/M020533/1, EP/M006093/1, EP/J020990/1] Funding Source: researchfish
  68. Medical Research Council [MR/L023784/1] Funding Source: researchfish

向作者/读者索取更多资源

The heterogeneity of neurodegenerative diseases is a key confound to disease understanding and treatment development, as study cohorts typically include multiple phenotypes on distinct disease trajectories. Here we introduce a machine-learning technique-Subtype and Stage Inference (SuStaIn)-able to uncover data-driven disease phenotypes with distinct temporal progression patterns, from widely available cross-sectional patient studies. Results from imaging studies in two neurodegenerative diseases reveal subgroups and their distinct trajectories of regional neurodegeneration. In genetic frontotemporal dementia, SuStaIn identifies genotypes from imaging alone, validating its ability to identify subtypes; further the technique reveals within-genotype heterogeneity. In Alzheimer's disease, SuStaIn uncovers three subtypes, uniquely characterising their temporal complexity. SuStaIn provides fine-grained patient stratification, which substantially enhances the ability to predict conversion between diagnostic categories over standard models that ignore subtype (p = 7.18 x 10(-4)) or temporal stage (p = 3.96 x 10(-5)). SuStaIn offers new promise for enabling disease subtype discovery and precision medicine.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据